Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.
Hans G. Nilsson’s long career at AstraZeneca AB (AZ) covered the period 1976–2006, first as a chemist and then, for several years, as Head of Research and Development of the extremely successful drug, Losec. In 1995 he was asked to set up a new AZ site in Boston, USA, and he and the family moved there. This eventually became AZ Boston and the facility was completed in 1999 with 400 employees. From 1995 to 2003 Hans G. served as CEO of the company. This was a highlight in a distinguished career. Hans G. eventually returned to Sweden, AZ Södertälje, now as Head of internal audit, a key research function in AZ; he reported to Claes Wilhelmsson, then Head of Research, AZ.
Hans G.’s and AZ’s paths parted ways in 2006 but he was far from finished with his career. He established his own consulting company and took on professional board member roles in different companies over the next years. An important assignment and a new challenge, among others, came through Hans G.’s passion for architecture. Johan Norén and Johan Casselbrant, Kanozi Arkitekter AB, got to know Hans G. when they designed laboratories in AZ Mölndal and Boston. Hans G. became Chairman of the Board of Kanozi Architects. He served as a mentor, and he contributed to the company’s strong growth. Hans G. always worked with a big heart, integrity, morality and ethics. His approach was always to set the tone at the top – aiming simply for a better society.
The desire to develop into areas close to Hans G.’s heart was never exhausted. In 2009, Hans started a new collaboration with the biopharmaceutical company PharmNovo (PN). When PN began the development of a compound for the treatment of chronic pain Hans G. became an essential part of the PN team and a key Board member. Hans was a strong organizer and never left a discussion without identifying the way ahead for the company. Although Hans G. had not worked directly with chemistry for many years, he started PN’s successful synthetic program for their candidate compound.
Hans G.’s bedrock in life was the family with his wife Christina and their three children, Pontus, Sofia and Emma, who currently live and work in Australia, Sweden and the USA respectively. Like many great talents, Hans G. was able to balance family and work lives. He shaped his work environment with an exceptional organizational ability, a strong will – and a lot of humanity.
We, in the PharmNovo leadership team, colleagues Per von Mentzer, Göran Lerenius, David Kendall and Bengt von Mentzer, mourn and miss our esteemed colleague and friend and will always remember Hans G. for the warm and generous person he was.
Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.
Hans G. Nilsson’s long career at AstraZeneca AB (AZ) covered the period 1976–2006, first as a chemist and then, for several years, as Head of Research and Development of the extremely successful drug, Losec. In 1995 he was asked to set up a new AZ site in Boston, USA, and he and the family moved there. This eventually became AZ Boston and the facility was completed in 1999 with 400 employees. From 1995 to 2003 Hans G. served as CEO of the company. This was a highlight in a distinguished career. Hans G. eventually returned to Sweden, AZ Södertälje, now as Head of internal audit, a key research function in AZ; he reported to Claes Wilhelmsson, then Head of Research, AZ.
Hans G.’s and AZ’s paths parted ways in 2006 but he was far from finished with his career. He established his own consulting company and took on professional board member roles in different companies over the next years. An important assignment and a new challenge, among others, came through Hans G.’s passion for architecture. Johan Norén and Johan Casselbrant, Kanozi Arkitekter AB, got to know Hans G. when they designed laboratories in AZ Mölndal and Boston. Hans G. became Chairman of the Board of Kanozi Architects. He served as a mentor, and he contributed to the company’s strong growth. Hans G. always worked with a big heart, integrity, morality and ethics. His approach was always to set the tone at the top – aiming simply for a better society.
The desire to develop into areas close to Hans G.’s heart was never exhausted. In 2009, Hans started a new collaboration with the biopharmaceutical company PharmNovo (PN). When PN began the development of a compound for the treatment of chronic pain Hans G. became an essential part of the PN team and a key Board member. Hans was a strong organizer and never left a discussion without identifying the way ahead for the company. Although Hans G. had not worked directly with chemistry for many years, he started PN’s successful synthetic program for their candidate compound.
Hans G.’s bedrock in life was the family with his wife Christina and their three children, Pontus, Sofia and Emma, who currently live and work in Australia, Sweden and the USA respectively. Like many great talents, Hans G. was able to balance family and work lives. He shaped his work environment with an exceptional organizational ability, a strong will – and a lot of humanity.
We, in the PharmNovo leadership team, colleagues Per von Mentzer, Göran Lerenius, David Kendall and Bengt von Mentzer, mourn and miss our esteemed colleague and friend and will always remember Hans G. for the warm and generous person he was.
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read morePharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read morePharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more